LYTIX — Lytix Biopharma AS Income Statement
0.000.00%
Last trade - 00:00
- NOK268.06m
- NOK217.52m
- NOK3.99m
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | NAS | NAS | NAS | NAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.31 | 0.003 | 0.017 | 1.41 | 3.99 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 34.1 | 42.4 | 48 | 67.1 | 101 |
Operating Profit | -33.8 | -42.4 | -48 | -65.7 | -96.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -33.2 | -42.1 | -48 | -56 | -87.9 |
Net Income After Taxes | -33.2 | -42.1 | -48 | -56 | -87.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -33.2 | -42.1 | -48 | -56 | -87.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -33.2 | -42.1 | -48 | -56 | -87.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.845 | -1.07 | -1.22 | -1.38 | -2.16 |